Improved quality of life after Ibandronic acid infusion in patients suffering from diffuse sclerosing osteomyelitis of the jaw.

IF 1.8 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE Medicina Oral Patologia Oral Y Cirugia Bucal Pub Date : 2024-11-01 DOI:10.4317/medoral.26761

T Frank, I Dewenter, S Otto, B-J Siegmund, W Smolka, T Hildebrandt, K-T Obermeier

{"title":"Improved quality of life after Ibandronic acid infusion in patients suffering from diffuse sclerosing osteomyelitis of the jaw.","authors":"T Frank, I Dewenter, S Otto, B-J Siegmund, W Smolka, T Hildebrandt, K-T Obermeier","doi":"10.4317/medoral.26761","DOIUrl":null,"url":null,"abstract":"Background: Quality of life research with respect to patient reported outcomes (PROs) other than pain has not yet been conducted in the field of Diffuse Sclerosing Osteomyelitis. This cross-sectional study aims to investigate changes in quality of life regarding 34 subjective parameters in patients with diffuse sclerosing osteomyelitis after intravenous Ibandronic acid administration (6mg).Material and methods: 15 patients (11 female, 4 male) with diffuse sclerosing osteomyelitis (DSO) treated with 6mg of Ibandronic acid completed the standardized questionnaires (EORTC QLQ-C30, EORTC QLQ-H&N35, OHIP-G 14) considering quality of life before and two weeks after infusion.Results: All 15 patients reported a significantly improved quality of life after administration of Ibandronate. Patients reported improvements in oral health associated quality of life as well as reduction of pain and intake of analgesics. In addition patients reported a significant improvement in fatigue, sexuality, social interactions, emotional, cognitive and role functioning. Furthermore patients reported an improvement in mouth opening, weight loss and loss of appetite as well as a reduction of speech and swallowing problems. Moreover, insomnia occurred less frequently after bisphosphonate infusions.Conclusions: The study evaluates patients subjectively benefit from a standardized Ibandronic acid regimen. A significantly improved quality of life after administration of Ibandronate was observed in all 15 patients.","PeriodicalId":49016,"journal":{"name":"Medicina Oral Patologia Oral Y Cirugia Bucal","volume":" ","pages":"e797-e805"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584957/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Oral Patologia Oral Y Cirugia Bucal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4317/medoral.26761","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Quality of life research with respect to patient reported outcomes (PROs) other than pain has not yet been conducted in the field of Diffuse Sclerosing Osteomyelitis. This cross-sectional study aims to investigate changes in quality of life regarding 34 subjective parameters in patients with diffuse sclerosing osteomyelitis after intravenous Ibandronic acid administration (6mg).

Material and methods: 15 patients (11 female, 4 male) with diffuse sclerosing osteomyelitis (DSO) treated with 6mg of Ibandronic acid completed the standardized questionnaires (EORTC QLQ-C30, EORTC QLQ-H&N35, OHIP-G 14) considering quality of life before and two weeks after infusion.

Results: All 15 patients reported a significantly improved quality of life after administration of Ibandronate. Patients reported improvements in oral health associated quality of life as well as reduction of pain and intake of analgesics. In addition patients reported a significant improvement in fatigue, sexuality, social interactions, emotional, cognitive and role functioning. Furthermore patients reported an improvement in mouth opening, weight loss and loss of appetite as well as a reduction of speech and swallowing problems. Moreover, insomnia occurred less frequently after bisphosphonate infusions.

Conclusions: The study evaluates patients subjectively benefit from a standardized Ibandronic acid regimen. A significantly improved quality of life after administration of Ibandronate was observed in all 15 patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

颌骨弥漫性硬化性骨髓炎患者输注伊班膦酸后生活质量的改善

背景：在弥漫性硬化性骨髓炎领域，除疼痛外，有关患者报告结果（PROs）的生活质量研究尚未开展。材料与方法：15 名弥漫性硬化性骨髓炎（DSO）患者（11 名女性，4 名男性）接受了 6 毫克伊班膦酸治疗，他们填写了标准化问卷（EORTC QLQ-C30、EORTC QLQ-H&N35、OHIP-G 14），考虑了输液前和输液后两周的生活质量：结果：所有 15 名患者均报告称，输注伊班膦酸钠后生活质量明显改善。患者表示口腔健康相关的生活质量有所改善，疼痛和止痛药的摄入量也有所减少。此外，患者在疲劳、性生活、社会交往、情感、认知和角色功能方面也有明显改善。此外，患者还表示张口、体重下降和食欲不振的情况有所改善，言语和吞咽问题也有所减少。此外，输注双膦酸盐后，失眠的发生率也降低了：该研究评估了患者从标准化伊班膦酸治疗方案中获得的主观益处。结论：该研究评估了患者从标准化伊班膦酸治疗方案中获得的主观益处，观察到所有 15 名患者在使用伊班膦酸治疗方案后生活质量明显改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medicina Oral Patologia Oral Y Cirugia Bucal DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

4.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： 1. Oral Medicine and Pathology: Clinicopathological as well as medical or surgical management aspects of diseases affecting oral mucosa, salivary glands, maxillary bones, as well as orofacial neurological disorders, and systemic conditions with an impact on the oral cavity. 2. Oral Surgery: Surgical management aspects of diseases affecting oral mucosa, salivary glands, maxillary bones, teeth, implants, oral surgical procedures. Surgical management of diseases affecting head and neck areas. 3. Medically compromised patients in Dentistry: Articles discussing medical problems in Odontology will also be included, with a special focus on the clinico-odontological management of medically compromised patients, and considerations regarding high-risk or disabled patients. 4. Implantology 5. Periodontology